Abstract: Compounds of formula (I) 1

Abstract: An overhead lighting appliance having a longitudinally extending and horizontally disposed lamp tube (4) housed within a reflector assembly of opposed downwardly diverging side reflectors (6) and cross blades (10) which divide the reflector assembly into cells and determine cut-off angles thus to reduce glare. Each cross blade (10) has an outer region (10a) to prevent ladder flash, which is of reduced or tapering thickness outwardly of a line C being a plane extending from the bottom of the reflector assembly to a tangent to an upper region of the lamp tube (4). The reduced width portion (10a) thus minimises obstruction of light output in the upper outer edge region of the cross blade.

Abstract: The invention relates to a process for preparing a substituted (6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidine compound of the formula (+)-I ##STR1## wherein: R, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently selected from the group consisting of hydrogen, halo, C.sub.1 -C.sub.6 alkyl, amino, --OCH.sub.3, --OCF.sub.3 and CF.sub.3, and the dotted line represents an optional double bond; comprising:enzymatically catalyzing the acylation of a compound of the formula (.+-.)-II ##STR2## wherein the variables are as defined above, and hydrolysing the product to obtain (+)-I.

Abstract: A process for the microbiological or enzymatic hydrolytic resolution of racemic trans-2-(alkoxycarbonylethyl) lactams of the formula I: ##STR1## wherein R is C.sub.1 -C.sub.7 alkyl, 2,2,2-trifluoroethyl or methoxyethoxyethyl and R.sup.1 is hydrogen or a protecting group is disclosed, whereby an optically enriched compound of the formula Ib or IIa: ##STR2## is obtained.

Abstract: A method for the treatment of cerebral vascular and neuronal degenerative disorders associated with learning, memory and cognitive dysfunctions including cerebral senility, multi-infarct dementia and senile dementia of the Alzheimer type and/or peripheral vascular disease and/or proliferative skin disease in mammals, such as humans, which comprises administering to the mammal in need of such treatment an effective amount of 1,3-di-n-butyl-7-(2-oxypropyl) xanthine or a pharmaceutically acceptable salt thereof.

Abstract: A method for the treatment and/or prophylaxis of cerebrovascular disorders and/or disorders associated with cerebral senility in mammals, such as humans, which comprises administering to the mammal in need of such treatment and/or prophylaxis an effective and/or prophylactic amount of a compound of formula (I): ##STR1## wherein (i) R.sub.1 is a group --X--CO--CH.sub.3 where X is a hydrocarbon radical having up to 4 carbon atoms which may be substituted by a methyl group,R.sub.2 and R.sub.3, which may be the same or different, each represents a straight-chain or branched-chain alkyl radical of 2 to 6 carbon atoms, or a cyclohexyl, alkoxyalkyl or hydroxyalkyl radical, andY and Z each represent oxygen;(ii) R.sub.1 is a group --CH.sub.2 (OR.sub.4)(OR.sub.5)CH.sub.3 wherein R.sub.4 is an alkyl radical of 1 to 4 carbon atoms and R.sub.5 is an alkyl radical of 1 to 4 carbon atoms or R.sub.4 is linked to R.sub.5 so that the OR.sub.4 and OR.sub.

Abstract: A class of di-(substituted phenoxy) alkanes having from 7 to 25 carbon atoms in the alkane moiety have hypolipidaemic activity.

Abstract: Pharmaceutical compositions having hypolipidaemic and/or hypoglycaemic activity, contain a substituted (4-carboxyphenoxy) phenyl alkane derivative.

Abstract: Pharmaceutical compositions having hypolipidaemic and/or hypoglycaemic activity, contain a substituted (4-carboxyphenoxy) phenyl alkane derivative.

Abstract: Pharmaceutical compositions having hypolipidaemic and/or hypoglycaemic activity, contain a substituted (4-carboxyphenoxy) phenyl alkane derivative.

Abstract: Certain non-ionic surfactants have been found to be useful in reducing serum cholesterol levels in animals and man. The surfactants are incorporated to at least 20 percent in pharmaceutical compositions so that the (C.sub.2 H.sub.4 O) groups amount to 0 to 30 percent of total molecular weight and the (C.sub.3 H.sub.6 O) groups have a partial molecular weight of 2250 to 3250. The surfactants are prepared by sequential addition of ethylene diamine. "Tetronic 701" and "Tetronic 702" are suitable; others of the same series are not.